Dizal Pharmaceutical Co Ltd. Stock Analysis 688192.SS

Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 1,009 full-time employees. The company went IPO on 2021-12-10. The firm focuses on the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The firm's main drug product is Sunvozertinib, which is used for patients with advanced NSCLC who have had disease progression after previous platinum-containing chemotherapy or are intolerant to platinum-containing chemotherapy and have confirmed EGFR Exon20ins mutation. The firm's other candidate drugs in pipeline are Golidocitinib, DZD8586, DZD2269, DZD1516 and DZD6008. The firm mainly conducts its businesses in the domestic market and overseas markets.